ProfileGDS5678 / 1436542_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 74% 71% 73% 74% 69% 75% 74% 74% 76% 75% 75% 76% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7417373
GSM967853U87-EV human glioblastoma xenograft - Control 24.8143474
GSM967854U87-EV human glioblastoma xenograft - Control 34.4525271
GSM967855U87-EV human glioblastoma xenograft - Control 44.8682773
GSM967856U87-EV human glioblastoma xenograft - Control 54.8979174
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2290269
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.818375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8045574
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8764174
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0640376
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.012175
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0323675
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0516176
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8823975